Novo Nordisk A/s Class B · OMXCOP:NOVO_B
Novo Nordisk A/s Class B — Investor Day (March 2024)
17 slides from Novo Nordisk A/s Class B's investor day presentation, Mar 7, 2024
Slide 1: Corporate strategy, Purpose and sustainability
Novo Nordisk® Corporate strategy Purpose and sustainability Lars Fruergaard Jørgensen President and CEO David Moore EVP Corporate Development 7 MARCH JUAN PABLO VILLASEÑOR Juan lives with obesity and cardiovascular disease Mexico
Slide 2: Forward-looking statements
2 Corporate strategy and purpose & sustainability Novo Nordisk® Forward-looking statements Novo Nordisk’s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including the statutory Annual Report 2023 and Form 20-F, which both were filed with the SEC in January 2024 i
Slide 3: Our purpose: Driving change to defeat serious chronic diseases
Novo Nordisk® Our purpose Driving change to defeat serious chronic diseases ROSHNI Roshni has type 1 diabetes India
Slide 4: Our corporate strategy remains focused
4 Corporate strategy and purpose & sustainability Novo Nordisk® Our corporate strategy remains focused Diabetes Obesity Strengthen leadership by Strengthen leadership through offering innovative medicines market development and by and driving patient offering innovative medicines outcomes and drivin
Slide 5: Strategic aspirations 2025 remain unchanged
5 Corporate strategy and purpose & sustainability Novo Nordisk® Strategic aspirations 2025 remain unchanged and continue to provide midterm direction on how to deliver on our strategy • Further raise the innovation-bar for diabetes treatment therapeutic focus • Progress towards zero environmental im
Slide 6: Building for future growth from a position of strength
6 Corporate strategy and purpose & sustainability Novo Nordisk® Building for future growth from a position of strength Growth beyond semaglutide loss of exclusivity remains a key priority Corporate strategic focus areas ILLUSTRATIVE Semaglutide compound patent loss of exclusivity 2031/32 Expand and
Slide 7: Agenda for today
7 Corporate strategy and purpose & sustainability Novo Nordisk® Agenda for today Timing Topic Timing Topic Strategy, research and supply 14.05 – 14.20 Q&A 09.10 – 09.25 Corporate strategy and purpose & sustainability 14.20 – 14.30 Break 09.25 – 09.50 Research & early development Break-out sessions 0
Slide 8: Novo Nordisk corporate strategy
8 Corporate strategy and purpose & sustainability Novo Nordisk® Novo Nordisk corporate strategy Diabetes Obesity Strengthen leadership by Strengthen leadership through offering innovative medicines market development and by and driving patient offering innovative medicines outcomes and driving patie
Slide 9: To enable long-term growth, having a clear portfolio strategy is essential
9 Corporate strategy and purpose & sustainability Novo Nordisk® To enable long-term growth, having a clear portfolio strategy is essential Building from a position of strength Investing where Novo Nordisk is best positioned to compete Value and growth potential Unmet need and landscape Content place
Slide 10: Diabetes and obesity remain the key priority areas in the corporate strategy
10 Corporate strategy and purpose & sustainability Novo Nordisk® Diabetes and obesity remain the key priority areas in the corporate strategy Therapy area priorities Portfolio focus Investment approach 1 Diabetes Obesity Broad and deep Key investment focus 2 CVD RBD Multiple targets in key segments
Slide 11: Translation from corporate strategic priorities to R&D pipeline
11 Corporate strategy and purpose & sustainability Novo Nordisk® Translation from corporate strategic priorities to R&D pipeline Diabetes Obesity Cardiovascular disease Rare blood disorders Maximise CagriSema Maximise CagriSema Maximise ziltivekimab Maximise Mim8 Near-term focus Progress projects in
Slide 12: R&D strategy amplified by business development execution
12 Corporate strategy and purpose & sustainability Novo Nordisk® R&D strategy amplified by business development execution Diabetes Obesity Cardiovascular disease Rare blood disorders INV-202 Ocedurenone Etavopivat Selected acquisitions and partnerships Peripheral focused ultrasound Ziltivekimab EPI0
Slide 13: Being a responsible business drives long-term value
13 Corporate strategy and purpose & sustainability Novo Nordisk® Being a responsible business drives long-term value Ownership structure creates long-term value Commitment to lead a sustainable business1 Novo Nordisk Foundation • Key objective: To provide a stable basis for Novo Nordisk and Novonesi
Slide 14: Novo Nordisk's ambition is zero environmental impact
14 Corporate strategy and purpose & sustainability Novo Nordisk® Novo Nordisk’s ambition is zero environmental impact CO2 emissions Plastic Biodiversity 2023 Emissions increased due to 2020 ReMedTM, Novo Nordisk’s • Committed to start making growth and CAPEX plastic take-back programme nature-relate
Slide 15: Social responsibility is core to Novo Nordisk
15 Corporate strategy and purpose & sustainability Novo Nordisk® Social responsibility is core to Novo Nordisk and initiatives focus on prevention, access and innovation Prevention Access Innovation • Cities Changing Diabetes to build • ~7 million people reached • Transformative treatments to health
Slide 16: Integrating ethics and compliance into every aspect of our business
16 Corporate strategy and purpose & sustainability Novo Nordisk® Integrating ethics and compliance into every aspect of our business Ethics and compliance are at the core of Novo Nordisk Steps taken to strengthen ethics and compliance setup Communication: Letters shared with HCPs reinforcing approve
Slide 17: Closing remarks
Novo Nordisk® Closing remarks Strategic aspirations 2025 remain unchanged and continue to provide midterm direction on how to deliver on our corporate strategy Diabetes and obesity remain the key priority areas in the focused corporate strategy Purpose and sustainability (ESG) is integrated in Novo